ConexiantFDA Approves First Oral PCSK9 Inhibitor

🚀 FDA Approval

The FDA has approved enlicitide (LIPFENDRA) as an adjunct to diet and exercise for LDL cholesterol reduction in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The approval makes enlicitide the first oral PCSK9 inhibitor, potentially expanding access to PCSK9-targeted therapy beyond injectable formulations.

Clinical Considerations

• Enlicitide is a once-daily 20-mg oral macrocyclic peptide that inhibits PCSK9 binding to LDL receptors.
• FDA approval was supported by the phase 3 CORALreef Lipids and CORALreef HeFH trials.
• In CORALreef Lipids, enlicitide achieved a 56% placebo-adjusted LDL-C reduction at week 24.
• In CORALreef HeFH, enlicitide achieved a 59% placebo-adjusted LDL-C reduction at week 24.
• Both studies also demonstrated reductions in non-HDL cholesterol and apolipoprotein B.
• Reported adverse-event rates were generally similar to placebo, although diarrhea and dizziness occurred more frequently in the HeFH trial.
• An ongoing cardiovascular outcomes study is evaluating effects on cardiovascular morbidity and mortality, which remain unproven at this time.

Practice Applications

• Recognize oral PCSK9 inhibition as a new treatment option for patients requiring substantial LDL-C lowering despite existing therapy.
• Consider the potential adherence advantages of an oral alternative to injectable PCSK9-directed therapies.
• Interpret approval based on LDL-C lowering and lipid biomarker outcomes rather than demonstrated cardiovascular event reduction.
• Monitor forthcoming cardiovascular outcomes data that will help define the drug’s long-term role in ASCVD prevention.